News >

CAR T Cells Bring Promise to Patients With ALL, DLBCL With Poor Prognosis

Brandon Scalea
Published: Tuesday, Mar 26, 2019

Lazaros J. Lekakis, MD

Lazaros J. Lekakis, MD

CAR T-cell therapy has brought newfound hope to patients with relapsed acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), where the outlook had traditionally been bleak, said Lazaros J. Lekakis, MD.

In patients with DLBCL, the CD19-directed CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) has not only generated excitement in the clinical trial space, but recent data have suggested the benefit is expanding in the real-world setting. Early results of a real-world population study demonstrated a median progression-free survival (PFS) of 6.18 months—in the ZUMA-1 trial, median PFS was 5.8 months.1 The overall response rate was 79% by day 30 post-infusion and 82% overall.

In ALL, the CD19-targeted product tisagenlecleucel (Kymriah) garnered attention for its encouraging data in the ELIANA study. In updated data presented at the 2018 ASH Annual Meeting, the 2-year relapse-free survival rate with the therapy was 62%.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x